Therefore, this study approached breast cancer treatment with a dual-targeted therapy targeting HER2-mediated signaling (TZ treatment) and Mcl-1 mRNA (Mcl-1 nioplex treatment). This evidence concerns the gene ERBB2 and breast carcinoma.